Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.
AffiliationPublic Health Laboratory, Withington Hospital, Manchester, UK.
MetadataShow full item record
AbstractPotential risk factors for CMV infection and the use of quantitative CMV PCR screening to guide pre-emptive anti-CMV therapy were reviewed retrospectively in 32 allogeneic bone marrow transplant patients accrued over a 2-year period. Significant CMV PCR positivity (an indicator of CMV infection) developed in 34% of patients. When analysed by recipient CMV IgG serostatus, 69% of seropositive recipients developed significant CMV PCR positivity while none of the seronegative recipients did so (P = 0.00007). Considering only the seropositive recipients, 100% of those who received the low intensity campath-1H/fludarabine/melphalan 'mini-allograft' conditioning regimen developed significant CMV PCR positivity, while only 44% of those who had received cyclophosphamide/TBI did so (P = 0.0337). The mean time to first episode of significant CMV PCR positivity for those who had received campath/fludarabine/melphalan was 25 days while for those who had received cyclophosphamide/TBI, this was 66 days (P = 0.0372). For the first episode of significant CMV PCR positivity, the mean index and peak CMV PCR counts for those who had received campath/fludarabine/melphalan were 4.54 and 5.22 log copies/ml respectively, while for cyclophosphamide/TBI, the corresponding figures were 3.85 and 4.12 log copies/ml respectively (P = 0.2986 and P = 0.0472 for index and peak values). 85% of those who had significant CMV PCR positivity with the campath/fludarabine/melphalan regimen developed more than one such episode, while 50% of those receiving cyclophosphamide/TBI regimen did so (P = 0.491). Significant CMV PCR positivity was associated with symptoms in a proportion of patients (pyrexia 45%, cough 18%, rise in AST 72%). No patient developed overt CMV disease. CMV PCR is useful for guiding pre-emptive anti-CMV therapy and for monitoring response.
CitationScreening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. 2001, 27 (3):301-6 Bone Marrow Transplant.
JournalBone Marrow Transplantation
- Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
- Authors: Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M
- Issue date: 2009 Jun
- Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
- Authors: Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, Goldstone AH, Linch DC, Mackinnon S
- Issue date: 2000 Dec
- Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
- Authors: Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK, Oertel J, Nitsche A, Siegert W
- Issue date: 2003 Oct
- Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
- Authors: Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N
- Issue date: 2010 Mar
- CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
- Authors: Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P
- Issue date: 2001 Oct